I bought furniture once, and the store owner helped me personally. After commenting on the relatively attractive prices, he replied, “I want to enrich myself. But I want to enrich myself slowly.”
Some investors have a similar philosophy. Earning money for a long time is perfectly fine with them. On the other hand, there are also investors who have a burning desire for big gains in a much shorter period.
There are three things investors in the latter category need:
- Enough money in advance to invest.
- High risk tolerance.
- The right shares to buy.
You will have to handle the first two items on your own. I will try to help with the third prerequisite. If you have $ 10,000 to invest and can withstand high levels of volatility, here are three growth stocks that could make you a quick fortune.
Image source: Getty Images.
Quickly: a tremendous advantage
I can’t think of many better stocks to buy in the bathroom than Quickly (NYSE: FSLY). After soaring more than 800% in early July from its lowest level in March, the technology stock has retreated more than 20%. But the opportunities for Fastly remain unchanged.
The company focuses on two related markets: content delivery networks (CDNs) and edge computing (processing at the edge of the cloud where organizations’ networks connect to the cloud). The ultimate goal for both CDNs and edge computing is to accelerate the speed at which users can access information over the Internet. Fastly’s technology meets this need for speed. The company recently announced that it achieved a key milestone of 100 terabits per second of connected edge capacity.
There is a major blow against Fastly. The company’s dizzying growth this year has given it a market capitalization of more than $ 8 billion. That’s a valuable valuation considering that Fastly is still not profitable and made just $ 63 million in sales in the first quarter.
But Fastly is chasing a total combined market in CDN and edge computing that is close to $ 35 billion. The market should continue to grow thanks to the increase in electronic commerce, online games and TV transmission. You quickly just have to capture a relatively small market share to be a much bigger winner than you already are.
Guardant Health: the DNA of a monster stock
Advances in genetic research offer much more than just letting you know more about your ancestry. An exciting advance offers the potential to revolutionize cancer diagnosis and treatment. And the company that is front and center in this field is Health guardant (NASDAQ: GH).
What is this breakthrough? Liquid biopsies. They are blood tests that can detect DNA fragments shed from cancer cells. Guardant Health’s revenues have skyrocketed thanks to the rapid adoption of its two liquid biopsy products, Guardant360 and GuardantOMNI. The above product helps match advanced stage cancer patients with the best treatment. The latter allows drug manufacturers to more effectively evaluate participants for clinical trials of experimental cancer therapies.
However, Guardant Health could really deliver on the promise of liquid biopsies with its two lunar trials. Both are still being evaluated in clinical studies at this time. The company hopes Lunar-1 will be useful in helping to make decisions for adjuvant cancer treatment and in monitoring cancer recurrence. Lunar-2 has tremendous potential to detect cancer in the early stages. Guardant Health recently reported positive results from a Lunar-2 clinical study in detecting early stage colon cancer.
Like Fastly, Guardant Health has a market capitalization of over $ 8 billion, but is not yet profitable yet. However, the pioneer of liquid biopsy should have an addressable market of $ 6 billion for its current products plus a potential market of more than $ 45 billion for its lunar trials if they are successful in clinical trials. I think Guardant Health will be a monstrous action for the next decade.
Livongo Health: providing a chronic tonic
Livongo Health (NASDAQ: LVGO) It stands out as another health care stock that has been a big winner but still has plenty of room to run. Its shares have risen about 340% more so far this year, thanks in large part to the COVID-19 pandemic.
The coronavirus outbreak caused health care taxpayers, such as government programs, insurers, and large self-insured employers, to notice the greatest risks for people with chronic conditions. Livongo provided a solution. Its digital health management platform uses data science to empower people with chronic conditions in ways that lead to better health outcomes and lower costs.
Livongo began with a primary focus on diabetes management. Its technology can also help people with other chronic conditions, such as hypertension and behavioral health problems. The company has been remarkably successful, collecting more than 30% of 2018 Fortune 500 as clients.
However, there is still a huge untapped market ahead of Livongo. You still have a small slice of the $ 28 million diabetes opportunity. Hypertension presents another potential annual market of $ 18.5 billion. And those numbers only include individuals in the US with these chronic conditions. Like Fastly and Guardant Health, Livongo seems like a great stock to buy if you want to make a quick fortune.
